Page 41 - Simulations Plus News Today : Breaking News, Live Updates & Top Stories | Vimarsana

SLP earnings call for the period ending November 30, 2020.

Company Profile Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Simulations Plus, Inc; Cognigen Corporation; DILIsym, and Lixoft. It generates maximum revenue from Simulations Plus, Inc segment. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) Predictor which is a computer program t...

Bio Simulation Market is Booming Worldwide with Certara, Simulations Plus, Dassault Systèmes  

News Category Global Banking & Finance Reviews Simulations Plus Enters New Funded Collaboration to Enhance Top-Rated GastroPlus® ACAT™ Model for Oral Absorption of Peptides Simulations Plus Enters New Funded Collaboration to Enhance Top-Rated GastroPlus® ACAT™ Model for Oral Absorption of Peptides Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced that it has entered into a new funded collaboration with a large pharmaceutical company to add novel me...

PUNE, INDIA, INDIA, December 27, 2020 /EINPresswire.com/ -- Biosimulation Market - 2019-2025 Report Description: Biosimulation is a technique in which computer programs are used for the simulation of biological processes. Biosimulation has wide reaching applications in the field of drug discovery and development of new drugs. It is a tool used for prediction and biosimulation is used to predict the future outcomes of current experiments related to discovery and development of new drugs. The process of drug discovery and development is a costly one, and the failure of the drug molecule in the ...